Stratatech Successfully Completes Clinical Trial Of StrataGraft® Skin Substitute - Trial’s Primary Clinical Endpoint Achieved
Oct 3rd 2008Drug InformationDermatology
Stratatech Corp. , a regenerative medicine company focused on the development and commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has successfully completed the multi-center, 15-patient clinical trial of its StrataGraft®
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
